The global metagenomics market share is expanding as genomic sequencing technologies gain wider application across healthcare, pharmaceutical research, agriculture, and environmental monitoring. According to Fortune Business Insights, the global metagenomics market size was valued at USD 2.99 billion in 2025. The market is projected to grow from USD 3.40 billion in 2026 to USD 9.52 billion by 2034, exhibiting a CAGR of 13.73% during the forecast period.
Metagenomics is the study of genetic material recovered directly from environmental or biological samples. Unlike conventional methods that require individual microorganisms to be cultured, this approach enables researchers to examine microbial communities collectively. It helps identify microorganisms, investigate microbial diversity, and understand the functions of genes within complex communities. These capabilities make metagenomics valuable for microbiome research, infectious disease detection, drug discovery, and environmental studies.
Growing interest in the human microbiome and the increasing use of next-generation sequencing are supporting the adoption of metagenomic technologies. Researchers are using these methods to study microbial interactions, investigate antimicrobial resistance, and identify potential applications in precision healthcare. The technology is also gaining attention in agricultural biotechnology, food safety, and wastewater monitoring, creating opportunities across multiple industries.
Leading companies in the global metagenomics market are focusing on sequencing technologies, laboratory products, and genomic analysis solutions. The major companies include:
Growing microbiome research: Increasing research into microbial communities is supporting demand for metagenomic sequencing. Researchers are examining the relationship between microorganisms and human health, including their potential roles in gastrointestinal conditions, immune responses, and other diseases. Metagenomics enables the analysis of complex microbial populations and supports investigations into microbial diversity and function. Pharmaceutical and biotechnology companies are also exploring microbiome-based therapeutic development, further supporting the use of these technologies.
Expansion of infectious disease surveillance: The growing need to identify pathogens and monitor antimicrobial resistance is encouraging the use of metagenomic methods. These technologies can help researchers detect microorganisms in complex samples and investigate emerging infectious threats. Their use in public health surveillance and environmental monitoring is creating additional demand for sequencing platforms and related analytical solutions.
High sequencing and data analysis costs: The adoption of metagenomics can be restricted by the cost of sequencing instruments, consumables, computational infrastructure, and data storage. Smaller laboratories and research institutions may face budget limitations when implementing high-throughput sequencing workflows. The need for specialized bioinformatics expertise also adds to operational expenses.